FilingReader Intelligence
Henlius reports profitable 2024, charts innovation and global growth
April 15, 2025 at 05:22 PM UTC•By FilingReader AI
** Shanghai Henlius Biotech (HKEX: 2696) reported a profitable 2024, with revenue reaching CNY 5,724.4 million and net profit at CNY 820.5 million, a 50.3% increase year-over-year. The company attributes its success to strong market performance and exceptional operational efficiency. Key growth drivers include consistent revenue from core products like HANQUYOU, HANSIZHUANG, HANLIKANG, HANDAYUAN and HANNAIJIA..
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
HKEX:2696•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Henlius Biotech, Inc publishes news
Free account required • Unsubscribe anytime